Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up.
The irreversible GABA transaminase inhibitor vigabatrin (VGB) was given in a single-blind fashion to 89 patients with complex partial seizures (CPS) refractory to conventional drugs. The median number of CPS per month decreased from 11.0 to 5.0 after addition of VGB, and 51% of patients had a 50% or greater decrease in CPS frequency (p less than 0.001). Side effects (principally drowsiness, ataxia, and headache) occurred mainly during the initiation of therapy and decreased during therapy. After 12 weeks on VGB, side effects significantly interfered with functioning in only 13% of patients, and the efficacy:toxicity ratio warranted continued administration in 74% of patients. Coadministration of VGB resulted in a mean decrease of 20% in phenytoin serum concentration (p less than 0.001). Sixty-six patients with a favorable response to VGB during the single-blind study have been followed for a median of 16.7 months on VGB. No serious systemic or neurologic toxicity has been detected, and most patients have retained their initial favorable CPS control.
D000614:Aminocaproates / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004347:Drug Interactions; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D020888:Vigabatrin
D000614:Aminocaproates; D000927:Anticonvulsants; D020888:Vigabatrin